Login with your work email address to view charts. No credit card required.
| Art Unit: | 1626 — Drug, bio-affecting and body treating compositions |
|---|---|
| Group: | 1620 — Biomedicinal Chemistry |
| Classes: |
514 — Drug, bio-affecting and body treating compositions 548 — Organic compounds -- part of the class 532-570 series 564 — Organic compounds -- part of the class 532-570 series 562 — Organic compounds -- part of the class 532-570 series 428 — Stock material or miscellaneous articles 556 — Organic compounds -- part of the class 532-570 series 544 — Organic compounds -- part of the class 532-570 series 552 — Organic compounds -- part of the class 532-570 series 560 — Organic compounds -- part of the class 532-570 series 549 — Organic compounds -- part of the class 532-570 series |
| Phone: | (571) 272-2919 |
| Email: | brandon.fetterolf@uspto.gov |
| Location: | VA 22314 |
| Title: | Supvy Pat Examnr Biolgy |
| Service: | 22 years |
| Grade: | GS-15 |
| 3-Year Grant rate: | 6% over 36 cases |
|---|---|
| Difficulty: | Extremely Hard |
| Difficulty Percentile: | 97th
|
With Examiner Fetterolf, you have a 6% chance of getting an issued patent by 3 years after the first office action. Examiner Fetterolf is an extremely hard examiner and in the 97th percentile across all examiners (with 100th percentile most difficult).
Below is the grant rate timeline for Examiner Fetterolf, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Examiner Fetterolf's grant rate is lower than that of Art Unit 1626 and lower than that of the USPTO.
| Average Office Actions Per Grant | |
|---|---|
| Examiner Fetterolf | 0.5 |
| Art Unit 1626 | 1.1 |
Examiner Fetterolf has granted 2 of 33 cases without any applicant-requested interviews for a grant rate of 6%.
Examiner Fetterolf has granted 0 of 3 cases with at least one applicant-requested interview for a grant rate of 0%.
With Examiner Fetterolf, conducting an interview decreases your chance of getting a patent granted by 100%.
| Number | Title | OA Rejections | Status | IFW |
|---|---|---|---|---|
| 18341503 | Inhibitors Of Met Kinase | Rejection information available with a Premium Stats subscription. See our pricing. | Patented | View |
| 18000943 | Method For Preparing A Crystalline Form Of Rabeximod | Patented | View | |
| 18024407 | Compounds Which Inhibit Rna Polymerase | Abandoned | View | |
| 18001371 | Solid Forms Of Apol1 Inhibitor And Methods Of Using Same | Patented | View | |
| 17914007 | Composite Pharmaceutical Composition For Treatment Of Fibrosis Disease | Abandoned | View | |
| 17920899 | Condensed Substituted Hydropyrroles As Antagonists Of The Muscarinic Acetylcholine Receptor M4 | Abandoned | View | |
| 18021100 | Parenteral Pharmaceutical Composition Comprising Cyclophosphamide And A Mixture Of Liquids | Abandoned | View | |
| 18041849 | 2-Aminoquinazolines As Lrrk2 Inhibitors, Pharmaceutical Compositions, And Uses Thereof | Patented | View | |
| 18210934 | New Quinazolinone Derivatives | Patented | View | |
| 18007925 | Methods Of Treating Prostate Cancer | Abandoned | View | |
| 18018221 | Substituted 1h-Pyrrolo[3,2-B]pyridine Compounds And Methods Of Use Thereof | Patented | View | |
| 18018435 | Temozolomide Analogs And Methods Of Use | Abandoned | View | |
| 18009972 | Modulators Of E3 Ligases | Abandoned | View | |
| 18007916 | Novel Thyroid Hormone Beta Receptor Agonist | Abandoned | View | |
| 18865805 | Combination Of Endocannabinoid And Mtor Inhibitors In The Treatment Of Neuroendocrine Neoplasms | Patented | View | |
| 17913843 | Methods Of Treating Covid-19 With Rifaximin | Abandoned | View | |
| 18009207 | Compounds For The Treatment Of Viral Infections | Abandoned | View | |
| 18000460 | N-Linked Macrocyclic 4-(Pyrazol-5-Yl)-Indole Derivatives As Inhibitors Of Mcl-1 | Abandoned | View | |
| 17924256 | Heterocyclic Compounds For The Control Of Invertebrate Pests | Abandoned | View | |
| 17918829 | Breast Cancer Therapeutic Agent | Abandoned | View | |
| 17996324 | Indazole Derivatives | Abandoned | View | |
| 17911455 | Method And Compositions For Treating, Preventing Or Limiting The Occurrence Of Viral Infection | Abandoned | View | |
| 17906651 | Treatment Of Type 2 Diabetes Or Obesity Or Overweight With 2-[(4-{6-[(4-Cyano-2-Fluorobenzyl)oxy]pyridin-2-Yl}piperidin-1-Yl)methyl]-1-[(2s)-Oxetan-2-Ylmethyl]-1h-Benzimidazole-6-Carboxylic Acid Or A Pharmaceutically Salt Thereof | Abandoned | View | |
| 17995341 | Ethanolamine Formulation For Treating Epithelial Ovarian Carcinoma | Abandoned | View | |
| 17926535 | Method For Preparing 2-Chloro-N-(1-Cyanocyclopropyl)-5-[2'-Methyl-5'-(Pentafluoroethyl)-4'-(Trifluoromethyl)-2'h-1,3'-Bipyrazol-4-Yl]benzamide | Patented | View | |
| 18023488 | Acrylamide Derivatives | Patented | View | |
| 18012287 | Combination Of A Cbp/p300 Bromodomain Inhibitor And A Kras Inhibitor For The Treatment Of Cancer | Patented | View | |
| 18009793 | Novel Analogs Of Pterostilbene Amino Acid Bearing Carbonates For Treating A Non-Alcoholic Fatty Liver Disease And Nonalcoholic Steatohepatitis | Patented | View | |
| 18253339 | Improved Process For The Preparation Of Trenbolone And/or Trenbolone Acetate | Patented | View | |
| 18000168 | Solid Forms Of Pralsetinib | Patented | View | |
| 18009671 | Compound And Method For The Treatment Of Coronaviruses | Abandoned | View | |
| 17920943 | Factor Xi Activation Inhibitors | Patented | View | |
| 17995091 | Pharmaceutically Acceptable Acid Salt Of Free Base Of Glp1 Receptor Agonist, And Preparation Method Therefor | Patented | View | |
| 17464713 | Inhaler Controller | Abandoned | View | |
| 17259467 | Diene Gemini Polymerizable Surfactants With Mixed Cis And Trans Isomers That Form Bicontinuous Cubic Phases | Abandoned | View | |
| 17607893 | A Crystalline Form Of (R)-Terbutaline Hydrochloride | Abandoned | View | |
| 16210466 | Composition Of Matter For Use In Organic Light-Emitting Diodes | Abandoned | View | |
| 16516592 | Nanoparticles And Preparation Method | Abandoned | View | |
| 17103514 | Apparatus, System And Method To Controllably Influence At Least One Of A Rate Of A Chemical Reaction, A Biological Process And/or Phase Transition Processes | Abandoned | View | |
| 16418707 | Information Exchange Using Gravitational Waves | Abandoned | View | |
| 16210414 | Composition Of Matter For Use In Organic Light-Emitting Diodes | Abandoned | View | |
| 16484301 | Process For The Production Of Lignin Derived Low Molecular Products | Abandoned | View | |
| 16484370 | Novel Compound, Organic Electroluminescent Element Using Same, And Electronic Device | Abandoned | View | |
| 17322420 | Organic Electroluminescent Compound And Organic Electroluminescent Device Comprising The Same | Abandoned | View | |
| 16978060 | Identification And Use Of Erk5 Inhibitor | Abandoned | View | |
| 16584020 | Color Stable Preservative Composition | Abandoned | View | |
| 17315249 | Covid-19 Therapeutics And Methods Of Treatment | Abandoned | View | |
| 16768871 | Febrifugine Derivatives | Abandoned | View | |
| 16921843 | Mu Opioid Receptor Modulators | Patented | View | |
| 16770438 | Compositions And Methods For Treating Hemorrhagic Stroke | Abandoned | View |
Subscribe to Premium Examiner Statistics for unlimited access for your law firm.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.